Resveratrol for Chronic Kidney Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Chronic Kidney Disease+1 MoreResveratrol - DietarySupplement
Eligibility
45 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether resveratrol can help improve vascular function in patients with CKD by reducing oxidative stress and inflammation.

Eligible Conditions
  • Chronic Kidney Disease
  • Endothelial Dysfunction

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Electronic Hookah Inhalation (- nicotine)
1
Supplemented with B-Complex
1
Blueberry Powder

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 6 weeks

6 weeks
Functional work capacity
Oxidative stress
Vascular endothelial function

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Electronic Hookah Inhalation (- nicotine)
1
Supplemented with B-Complex
1
Blueberry Powder

Side Effects for

Resveratrol
25%Headache
8%Abdominal pain
8%Sickness
This histogram enumerates side effects from a completed 2013 Phase 2 trial (NCT02114892) in the Resveratrol ARM group. Side effects include: Headache with 25%, Abdominal pain with 8%, Sickness with 8%.

Trial Design

2 Treatment Groups

Resveratrol
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

25 Total Participants · 2 Treatment Groups

Primary Treatment: Resveratrol · Has Placebo Group · N/A

Resveratrol
DietarySupplement
Experimental Group · 1 Intervention: Resveratrol · Intervention Types: DietarySupplement
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Resveratrol
2014
Completed Phase 3
~730

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks

Who is running the clinical trial?

Diana JalalLead Sponsor
1 Previous Clinical Trials
88 Total Patients Enrolled

Eligibility Criteria

Age 45 - 80 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The person took an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for more than three months before the study.
Kidney disease stage III is estimated to have a GFR of between 30 and 60 milliliters per minute per 1.73 square meters.
You have type II diabetes mellitus.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top